Clinical Trial Update: A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BIBF1120 (nintedanib) in platinum-sensitive small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Small Cell Lung Cancer, Platinum-sensitive | Phase 2 | Status: WITHDRAWN